An OpEd in The New York Times (below) is trumpeting psychiatry’s latest “cure” for depression: it requires surgical implantation of electrodes in the brain, continued “maintenance” with powerful psychotropic drugs, and it costs $40,000.
Below a press release from the lawfirm, Baum Hedlund, announces it has filed a class action lawsuit against GlaxoSmithKline charging the company with fraud, negligence, strict liability, and breach of warranty in its marketing of Paxil (Seroxat) by concealing the risk of suicide.
The Associated Press reports that a just released study that found that a staggering, two and half million children in the U.S. are being prescribed antipsychotics annually–that’s 40 out of every 1,000 children.
"Biological psychiatrists have looked very closely for a serotonin imbalance or dysfunction in patients with depression or obsessive compulsive disorder and, to date, it has been elusive," says Dr. Wayne Goodman, Chair of the US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee.
The Arkansas Democrat Gazette reports (below): "TeenScreen, developed by a Columbia University professor, has come under intense criticism nationally."
The Boston Globe reports (below): “More than 50 years after psychiatrists began widely dispensing drugs to treat mental illness, the profession is coming face to face with a humbling reality: Its treatments often fail, leaving millions of patients [ ] to suffer while doctors search for something that works.”
Dr. Peter Breggin’s sealed expert medical report in a Paxil liability case is now in the public domain.
From both sides of the Atlantic, even psychiatrists are acknowledging–the ADHD diagnosis makes no sense.
An analysis published in the current issue of the British J of Psychiatry (BJP) of the suicide rate among schizophrenia patients treated at the same hospital in North Wales (UK) before psychotropic drugs and patients treated (in and out of hospital) with neuroleptics and /or atypical antipsychotics, found a 20-fold increase in the suicide rate since use of psychotropic drugs.
"During a hastily called press conference yesterday,” the FDA announced that it is considering ADDITIONAL warnings on the labels of SSRI drugs—Prozac, Paxil, Zoloft, et al.
It is astonishing how untrustworthy loosely given advice about the safety of SSRI antidepressants by medical professionals and academic institutions.
